


Lurasidone Hydrochloride

Cat. No.:	HY-B0032
CAS No.:	367514-88-3
Molecular Formula:	C ₂₈ H ₃₇ ClN ₄ O ₂ S
Molecular Weight:	529
Target:	5-HT Receptor; Dopamine Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 6.67 mg/mL (12.61 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to)
 Ethanol : 2 mg/mL (3.78 mM; Need ultrasonic)
 H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.8904 mL	9.4518 mL	18.9036 mL
	5 mM	0.3781 mL	1.8904 mL	3.7807 mL
	10 mM	0.1890 mL	0.9452 mL	1.8904 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 0.67 mg/mL (1.27 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 0.67 mg/mL (1.27 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is an antagonist of both dopamine D₂ and 5-HT₇ with IC₅₀s of 1.68 and 0.495 nM, respectively. Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is also a partial agonist of 5-HT_{1A} receptor with an IC₅₀ of 6.75 nM.

IC₅₀ & Target

5-HT ₇ Receptor 0.495 nM (IC ₅₀)	5-HT _{1A} Receptor 6.75 nM (IC ₅₀)	D ₂ Receptor 1.68 nM (IC ₅₀)
--	--	--

In Vitro

Lurasidone (SM-13496) Hydrochloride is an antagonist of dopamine D₂ and 5-HT₇ with IC₅₀s of 1.68±0.09 and 0.495±0.090 nM, respectively. Lurasidone (SM-13496) Hydrochloride is also a partial agonist of 5-HT_{1A} receptor with an IC₅₀ of 6.75±0.97

nM. In vitro receptor binding experiments reveal that Lurasidone (SM-13496) Hydrochloride demonstrates affinity for dopamine D₂ and 5-HT_{2A} receptors higher than other tested antipsychotics. Lurasidone does not increase [³⁵S]GTPγS binding to the membrane preparations for dopamine D₂ receptors by itself, but it antagonizes dopamine-stimulated [³⁵S]GTPγS binding in a concentration-dependent manner with a K_B value of 2.8±1.1 nM^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Lurasidone (SM-13496) Hydrochloride dose-dependently increases the ratio of DOPAC/dopamine in both regions, but it shows a preferential effect on the frontal cortex compare with the striatum, especially at higher doses. Lurasidone (SM-13496) Hydrochloride (ED₅₀ values 2.3 to 5.0 mg/kg) shows a comparable potency with olanzapine (ED₅₀ values 1.1 to 5.1 mg/kg), higher potency than clozapine (ED₅₀ 9.5 to 290 mg/kg), and slightly lower potency than haloperidol (ED₅₀ values 0.44 to 1.7 mg/kg). Lurasidone (SM-13496) Hydrochloride (1 to 10 mg/kg) dose-dependently inhibits conditioned avoidance response (CAR) in rats, and the ED₅₀ values are 6.3 mg/kg. Lurasidone (SM-13496) Hydrochloride dose-dependently inhibits TRY-induced forepaw clonic seizure and p-CAMP-induced hyperthermia with ED₅₀ values of 5.6 and 3.0 mg/kg, respectively. Lurasidone (SM-13496) Hydrochloride (0.3 to 30 mg/kg) dose-dependently and significantly increases the number of shocks received by rats in the conflict test with MED of 10 mg/kg (p<0.01)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[1]

SD rats are individually isolated in clear plastic cages and injected with methamphetamine (MAP) (1 mg/kg i.p.) 1 h after the administration of drugs or vehicle. In the test of persistence of the effect, Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is administered 1, 2, 4, and 8 h before the MAP injection. Locomotor activity is measured for 80 min from 10 min after MAP injection. Four or five groups of 6 to 13 rats are used to calculate the ED₅₀ value that inhibits MAP-induced hyperactivity by 50% of the animals tested^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nature. 2023 Dec;624(7992):672-681.
- bioRxiv. 2024 Jan 14.
- Marmara Pharm J. 2017;21 (4): 931-937.
- Marmara Pharm J. 2017;21 (4): 931-937.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Ishibashi T, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010 Jul;334(1):171-81.
- [2]. Sakine Atila Karaca, et al. Development of a validated high-performance liquid chromatographic method for the determination of Lurasidone in pharmaceuticals. Marmara Pharm J. 2017;21 (4): 931-937.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA